Skip to main content

Articles

Page 2 of 34

  1. The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established.

    Authors: José Luis Piñana, Lucia López-Corral, Rodrigo Martino, Lourdes Vazquez, Ariadna Pérez, Gabriel Martin-Martin, Beatriz Gago, Gabriela Sanz-Linares, Andrés Sanchez-Salinas, Lucia Villalon, Venancio Conesa-Garcia, María T. Olave, Magdalena Corona, Sara Marcos-Corrales, Mar Tormo, José Ángel Hernández-Rivas…
    Citation: Journal of Hematology & Oncology 2022 15:54
  2. Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of ...

    Authors: Wenhan Yang, Kaiping Gao, Youhui Qian, Yongyi Huang, Qin Xiang, Cheng Chen, Qianqian Chen, Yiling Wang, Fuyuan Fang, Qihan He, Siqi Chen, Juan Xiong, Yangchao Chen, Ni Xie, Duo Zheng and Rihong Zhai
    Citation: Journal of Hematology & Oncology 2022 15:53
  3. LncRNA-PACERR plays critical role in the polarization of tissue-associated macrophages (TAMs). In this study, we found the function and molecular mechanism of PACERR in TAMs to regulate pancreatic ductal adeno...

    Authors: Yihao Liu, Minmin Shi, Xingfeng He, Yizhi Cao, Pengyi Liu, Fanlu Li, Siyi Zou, Chenlei Wen, Qian Zhan, Zhiwei Xu, Jiancheng Wang, Baofa Sun and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:52
  4. Authors: Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh and Alan Prem Kumar
    Citation: Journal of Hematology & Oncology 2022 15:50

    The original article was published in Journal of Hematology & Oncology 2022 15:18

  5. Chromatin has distinct three-dimensional (3D) architectures important in key biological processes, such as cell cycle, replication, differentiation, and transcription regulation. In turn, aberrant 3D structure...

    Authors: Siwei Deng, Yuliang Feng and Siim Pauklin
    Citation: Journal of Hematology & Oncology 2022 15:49
  6. Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Pr...

    Authors: Amanda Khoo, Lydia Y. Liu, Taylor Y. Sadun, Amirali Salmasi, Aydin Pooli, Ely Felker, Kathleen E. Houlahan, Vladimir Ignatchenko, Steven S. Raman, Anthony E. Sisk Jr., Robert E. Reiter, Paul C. Boutros and Thomas Kislinger
    Citation: Journal of Hematology & Oncology 2022 15:48
  7. The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut m...

    Authors: Yuting Lu, Xiangliang Yuan, Miao Wang, Zhihao He, Hongzhong Li, Ji Wang and Qin Li
    Citation: Journal of Hematology & Oncology 2022 15:47
  8. Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of individual patients holds promise for tumors with high genetic heterogeneity, potentially enabling eradication of the tumor in its...

    Authors: Bingfeng Zuo, Yang Zhang, Kangjie Zhao, Li Wu, Han Qi, Rong Yang, Xianjun Gao, Mengyuan Geng, Yingjie Wu, Renwei Jing, Qibing Zhou, Yiqi Seow and HaiFang Yin
    Citation: Journal of Hematology & Oncology 2022 15:46
  9. Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabo...

    Authors: Huai-liang Wu, Yue Gong, Peng Ji, Yi-fan Xie, Yi-Zhou Jiang and Guang-yu Liu
    Citation: Journal of Hematology & Oncology 2022 15:45
  10. Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as ...

    Authors: Minru Liao, Rui Qin, Wei Huang, Hong-Ping Zhu, Fu Peng, Bo Han and Bo Liu
    Citation: Journal of Hematology & Oncology 2022 15:44
  11. Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (FcγRs) pla...

    Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige…
    Citation: Journal of Hematology & Oncology 2022 15:42
  12. Chromosome translocations involving mixed lineage leukemia 1 (MLL1) cause acute leukemia in most infants and 5–10% children/adults with dismal clinical outcomes. Most frequent MLL1-fusion partners AF4/AFF4, AF...

    Authors: Xin Li, Yuan Yao, Fangrui Wu and Yongcheng Song
    Citation: Journal of Hematology & Oncology 2022 15:41
  13. Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated wit...

    Authors: Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka…
    Citation: Journal of Hematology & Oncology 2022 15:40
  14. Persistence of CAR-T cell function is associated with relapse rate after CAR-T therapy, while co-stimulatory agents are highly concerned with the persistence of CAR-T cells. In this study, we designed and cons...

    Authors: Jingwen Tan, Yujie Jia, Meixia Zhou, Chengcheng Fu, Israth Jahan Tuhin, Jing Ye, Masuma Akter Monty, Nan Xu, Liqing Kang, Minghao Li, Jiaqi Shao, Xiaoyan Fang, Hongjia Zhu, Lingzhi Yan, Changju Qu, Shengli Xue…
    Citation: Journal of Hematology & Oncology 2022 15:39
  15. Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor micr...

    Authors: Tao Xia, Keyu Li, Nan Niu, Yingkuan Shao, Ding Ding, Dwayne L. Thomas, Hao Jing, Kenji Fujiwara, Haijie Hu, Arsen Osipov, Chunhui Yuan, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Jin He, Yiping Mou…
    Citation: Journal of Hematology & Oncology 2022 15:37
  16. F-18 fluorodeoxyglucose positron emission tomography computed tomography (PET/CT) is used to assess response of non-Hodgkin lymphoma (NHL) to chimeric antigen receptor T cell (CAR-T) therapy. We sought to desc...

    Authors: William G. Breen, Matthew A. Hathcock, Jason R. Young, Roman O. Kowalchuk, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas Bisneto, Yucai Wang, Stephen M. Ansell, Jennifer L. Peterson, Patrick B. Johnston, Scott C. Lester and Yi Lin
    Citation: Journal of Hematology & Oncology 2022 15:36
  17. Cancer microenvironment is critical for tumorigenesis and cancer progression. The extracellular matrix (ECM) interacts with tumor and stromal cells to promote cancer cells proliferation, migration, invasion, a...

    Authors: Yangfu Jiang, Hongying Zhang, Jiao Wang, Yongliang Liu, Ting Luo and Hui Hua
    Citation: Journal of Hematology & Oncology 2022 15:34
  18. Authors: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian…
    Citation: Journal of Hematology & Oncology 2022 15:33

    The original article was published in Journal of Hematology & Oncology 2022 15:1

  19. Hepatocellular carcinoma (HCC) is well-known to be a highly prevalent malignant tumor, but the treatment of this pathological state has been still challenging. Solamargine (SM), a traditional Chinese herb-deri...

    Authors: Shuangshuang Yin, Wenke Jin, Yuling Qiu, Leilei Fu, Tao Wang and Haiyang Yu
    Citation: Journal of Hematology & Oncology 2022 15:32
  20. Natural killer (NK) cells are the predominant innate lymphoid cells that mediate anti-viral and anti-tumor immunity. NK cells arise from hematopoietic stem cells in the bone marrow (BM) and undergo lineage spe...

    Authors: Shoubao Ma, Michael A. Caligiuri and Jianhua Yu
    Citation: Journal of Hematology & Oncology 2022 15:31
  21. Isocitrate dehydrogenase-2 (IDH2) is a mitochondrial enzyme that catalyzes the metabolic conversion between isocitrate and alpha-ketoglutarate (α-KG) in the TCA cycle. IDH2 mutation is an oncogenic event in ac...

    Authors: Peiting Zeng, Wenhua Lu, Jingyu Tian, Shuang Qiao, Jiangjiang Li, Christophe Glorieux, Shijun Wen, Hui Zhang, Yiqing Li and Peng Huang
    Citation: Journal of Hematology & Oncology 2022 15:30
  22. Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable success in the treatment of hematologic malignancies, while the success has not yet been replicated in solid tumors. To some extent, t...

    Authors: Zhichen Sun, Rutian Li, Yun Shen, Siyi Tan, Naiqing Ding, Ruihan Xu, Xinyue Wang, Jia Wei, Baorui Liu and Fanyan Meng
    Citation: Journal of Hematology & Oncology 2022 15:29
  23. Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in th...

    Authors: Jian Liu, Minyang Fu, Manni Wang, Dandan Wan, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2022 15:28
  24. Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRN...

    Authors: Mathieu Leclerc, Rabah Redjoul, Anne Le Bouter, Florence Beckerich, Christine Robin, Vincent Parinet, Cécile Pautas, Dehbia Menouche, Selwa Bouledroua, Lydia Roy, Ludovic Cabanne, Yakout Nait-Sidenas, Slim Fourati and Sébastien Maury
    Citation: Journal of Hematology & Oncology 2022 15:27
  25. High-grade B-cell lymphoma with translocations involving MYC and BCL2 or BCL6, usually referred to as double hit lymphoma (DHL), is an aggressive hematological malignance with distinct genetic features and poor c...

    Authors: Yuxin Zhuang, Jinxin Che, Meijuan Wu, Yu Guo, Yongjin Xu, Xiaowu Dong and Haiyan Yang
    Citation: Journal of Hematology & Oncology 2022 15:26
  26. Acute myeloid leukemia (AML) patients suffer dismal prognosis upon treatment resistance. To study functional heterogeneity of resistance, we generated serially transplantable patient-derived xenograft (PDX) mo...

    Authors: Christina Zeller, Daniel Richter, Vindi Jurinovic, Ilse A. Valtierra-Gutiérrez, Ashok Kumar Jayavelu, Matthias Mann, Johannes W. Bagnoli, Ines Hellmann, Tobias Herold, Wolfgang Enard, Binje Vick and Irmela Jeremias
    Citation: Journal of Hematology & Oncology 2022 15:25
  27. Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have grea...

    Authors: Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang and Yong Xia
    Citation: Journal of Hematology & Oncology 2022 15:24
  28. KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However,...

    Authors: Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng and Daohong Zhou
    Citation: Journal of Hematology & Oncology 2022 15:23
  29. Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the efficacy and sa...

    Authors: Ke Zhao, Ren Lin, Zhiping Fan, Xiaoyong Chen, Yu Wang, Fen Huang, Na Xu, Xi Zhang, Xin Zhang, Li Xuan, Shunqing Wang, Dongjun Lin, Lan Deng, Danian Nie, Jianyu Weng, Yonghua Li…
    Citation: Journal of Hematology & Oncology 2022 15:22
  30. The circadian rhythm is an evolutionarily conserved time-keeping system that comprises a wide variety of processes including sleep–wake cycles, eating–fasting cycles, and activity–rest cycles, coordinating the...

    Authors: Li Zhou, Zhe Zhang, Edouard Nice, Canhua Huang, Wei Zhang and Yong Tang
    Citation: Journal of Hematology & Oncology 2022 15:21
  31. Sickle cell disease (SCD), which affects approximately 100,000 individuals in the USA and more than 3 million worldwide, is caused by mutations in the βb globin gene that result in sickle hemoglobin production...

    Authors: A. M. Brandow and R. I. Liem
    Citation: Journal of Hematology & Oncology 2022 15:20
  32. The heterogeneity and the complex cellular architecture have a crucial effect on breast cancer progression and response to treatment. However, deciphering the neoplastic subtypes and their spatial organization...

    Authors: Si-Qing Liu, Zhi-Jie Gao, Juan Wu, Hong-Mei Zheng, Bei Li, Si Sun, Xiang-Yu Meng and Qi Wu
    Citation: Journal of Hematology & Oncology 2022 15:19
  33. Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in encoding proteins. However, they participate in developmental and biological processes and their abnormal expression affects c...

    Authors: Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh and Alan Prem Kumar
    Citation: Journal of Hematology & Oncology 2022 15:18

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:50

  34. Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of malignant plasma cells nurtured within a permissive bone marrow microenvironment. While patients mount numerous adaptive immu...

    Authors: Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, Ehsan Malek and James J. Driscoll
    Citation: Journal of Hematology & Oncology 2022 15:17
  35. The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug dev...

    Authors: Dawei Wu, Huiyao Huang, Minghui Zhang, Ziwei Li, Shuhang Wang, Yue Yu, Yuan Fang, Ning Jiang, Huilei Miao, Peiwen Ma, Yu Tang and Ning Li
    Citation: Journal of Hematology & Oncology 2022 15:16
  36. Patients with cancer have an increased risk of coronavirus disease 2019 (COVID-19) and an attenuated responses to various vaccines. This meta-analysis aims to assess the serologic response to COVID-19 vaccinat...

    Authors: Atsushi Sakuraba, Alexander Luna and Dejan Micic
    Citation: Journal of Hematology & Oncology 2022 15:15
  37. Non-coding RNAs (ncRNAs) have been defined as a class of RNA molecules transcribed from the genome but not encoding proteins, such as microRNAs, long non-coding RNAs, Circular RNAs, and Piwi-interacting RNAs. ...

    Authors: Rongyan Zhao, Jiahui Fu, Lingjuan Zhu, Yi Chen and Bo Liu
    Citation: Journal of Hematology & Oncology 2022 15:14
  38. RNA modification plays a crucial role in many biological functions, and its abnormal regulation is associated with the progression of cancer. Among them, N6-methyladenine (m6A) is the most abundant RNA modificati...

    Authors: Qian Guan, Huiran Lin, Lei Miao, Huiqin Guo, Yongping Chen, Zhenjian Zhuo and Jing He
    Citation: Journal of Hematology & Oncology 2022 15:13
  39. Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for ...

    Authors: Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran…
    Citation: Journal of Hematology & Oncology 2022 15:12
  40. Limited previous studies focused on the death and progression risk stratification of colorectal cancer (CRC) lung metastasis patients. The aim of this study is to construct a nomogram model combing machine lea...

    Authors: Renjie Wang, Weixing Dai, Jing Gong, Mingzhu Huang, Tingdan Hu, Hang Li, Kailin Lin, Cong Tan, Hong Hu, Tong Tong and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2022 15:11
  41. The members of the Poly(ADP‐ribose) polymerase (PARP) superfamily are involved in several biological processes and, in particular, in the DNA damage response (DDR). The most studied members, PARP1, PARP2 and P...

    Authors: Antonella Padella, Andrea Ghelli Luserna Di Rorà, Giovanni Marconi, Martina Ghetti, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Hematology & Oncology 2022 15:10
  42. Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonge...

    Authors: Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, Olga Nigro, Luca Cantini, Massimo Di Maio, Joachim G. J. V. Aerts, Emilio Bria, Federica Bertolini, Miriam Grazia Ferrara, Michele Ghidini, Francesco Grossi…
    Citation: Journal of Hematology & Oncology 2022 15:9
  43. RNA demethylase ALKBH5 takes part in the modulation of N6-methyladenosine (m6A) modification and controls various cell processes. ALKBH5-mediated m6A demethylation regulates gene expression by affecting multiple ...

    Authors: Jianwei Qu, Haimeng Yan, Yifan Hou, Wen Cao, Yang Liu, Enfan Zhang, Jingsong He and Zhen Cai
    Citation: Journal of Hematology & Oncology 2022 15:8
  44. Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and sched...

    Authors: Christophe Maritaz, Sophie Broutin, Nathalie Chaput, Aurélien Marabelle and Angelo Paci
    Citation: Journal of Hematology & Oncology 2022 15:6
  45. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patter...

    Authors: No-Joon Song, Carter Allen, Anna E. Vilgelm, Brian P. Riesenberg, Kevin P. Weller, Kelsi Reynolds, Karthik B. Chakravarthy, Amrendra Kumar, Aastha Khatiwada, Zequn Sun, Anjun Ma, Yuzhou Chang, Mohamed Yusuf, Anqi Li, Cong Zeng, John P. Evans…
    Citation: Journal of Hematology & Oncology 2022 15:5
  46. There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.

    Authors: P. Guisado-Vasco, M. M. Carralón-González, J. Aguareles-Gorines, E. M. Martí-Ballesteros, M. D. Sánchez-Manzano, D. Carnevali-Ruiz, M. García-Coca, R. Barrena-Puertas, R. García de Viedma, J. M. Luque-Pinilla, G. Sotres-Fernandez, J. M. Fernández-Sousa, X. E. Luepke-Estefan, J. A. López-Martín and J. M. Jimeno
    Citation: Journal of Hematology & Oncology 2022 15:4

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here